Application of a white and green spectrofluorimetric approach for facile quantification of amlodipine, a hypotensive drug, in batch materials, dosage forms, and biological fluids; content homogeneity testing.

The suggested study adheres to a particular protocol to ensure that the process is environmentally friendly and sustainable. It is worth mentioning that several tools have been adopted as prospective measures of the method greenness. Fortunately, the established analytical method is identified as white by the white analytical chemistry (WAC) concept, which uses the red/ green/blue color scheme (RGB 12 tool) to combine ecological and functional factors for the first time in studying of the cited drug. Amlodipine (AMD), a cardiovascular treating agent, belongs to the dihydropyridine class of oral calcium channel-blocking agents. This article presents a novel, simple, green, one-pot-processed, fast, and ultrasensitive fluorimetric approach for monitoring and assessment of AMD using molecular-size-dependent fluorescence augmentation of the light scattering-driven signal of eosin, a biological stain at a wavelength of 415 nm. This enhancement was directly proportional to the size of the produced complex. The linearity range was from 30 to 900 ng mL-1 , with corresponding sensitivity limits (detection and quantitation levels) of 9.2 and 28 ng mL-1 , respectively. The planned approach was also successfully used to track AMD content in bulk, dosage forms, and bio-fluids (human plasma and urine). The developed method's eco-friendliness was established by different eco-rating metric tools.

An eco-friendly matrix-augmented fluorescence spectroscopic approach for the analysis of mitoxantrone, an oncogenic therapy; application to the dosage form and biological matrices.

Mitoxantrone (MXN) is a synthetic anthracenedione oncogenic therapy. It is often prescribed as an anticancer agent to manage a variety of cancers. A green, fast, and easy fluorimetric technique for the assay of MXN as a topoisomerase type II enzyme suppressor. An investigation of MXN's fluorescence behavior in various media and solvents constituted the basis for this new technique. Methanol was shown to enhance the intrinsic fluorescence considerably. After excitation at 610 nm, the highest fluorescence intensity was found at 675 nm. Various experimental parameters, such as media, solvents, and pH levels, were tested and adjusted. ICH (International Conference on Harmonization) guidelines were followed when validating procedures. It was possible to achieve linearity in the 0.02-1.50 µg ml-1 with the method. The sensitivity (in terms of limit of detection and limit of quantification) was 0.003 and 0.008 µg ml-1 , indicating low toxicity. As a result, the current technology has a remarkable recovery for detecting residues in diverse bodily fluids. Also, the quantum yield was estimated for the designed system. Finally, the method was rated by eco-scale scoring.

Investigating the interaction of mitoxantrone with anionic surfactants by spectrofluorimetry and its application for the feasible analysis of pharmaceutical preparation and biological fluids.

The behaviour of mitoxantrone (MTX), an anthracenedione antineoplastic agent, in different types of organized medium was explored using molecular spectrofluorometry. The original fluorescence and quantum yield of MTX were augmented by about five-fold in the aqueous buffered solution (Britton-Robinson, pH 3.0) by the addition of sodium dodecyl sulfate. Enhancement in the fluorescence intensity did not come from the boost in the ultraviolet (UV) light absorbance of the drug in the presence of micelles but due to shielding of the lowest excited singlet state of the drug from a radiationless process inside the cavity of the micelle. Accordingly, a versatile, sensitive, and feasible spectrofluorimetric method was constructed and evaluated for MTX determination. Fluorescence measurements were performed at 675 nm (λex 610 nm). A linear relationship was shown between fluorescence intensity and drug concentration within the range 0.01-2.0 µg ml-1 of MTX with a correlation coefficient of 0.9999 and a detection limit of 2 ng ml-1 . The developed method was effectively used for analysis of MTX in biological samples and dosage forms. In addition, the method was expanded to study the stability of MTX exposed to different drastic degradations and the kinetic parameters of the degradation were calculated.

Integrated spectroscopic approaches for the facile one pot quantification of olanzapine in pharmaceutical formulation and spiked human plasma.

In this work, the xanthene dye, erythrosine B, was employed as a probe for the determination of olanzapine using two fast and highly simple analytical approaches. The assay was based on the formation of a binary complex between the drug and erythrosine B in a slightly acidic aqueous buffered solution. In the first method, the absorbance of the formed product was monitored at 558 nm. The reaction stoichiometry was investigated, and the stability constant of the formed complex was estimated. The linear range of the method that obeyed Beer's law was in the concentration range of 0.6-8.0 µg/ml. The calculated detection and quantitation limits were 0.2 and 0.6 µg/mL. Upon adding the drug solution to erythrosine B, the native fluorescence of the dye was quenched and monitored at 550 nm after excitation at 528 nm. Thus, the fluorescence quenching was utilized as the quantitative signal in the spectrofluorimetric approach. The extent of quenching in the fluorescence intensity was rectilinear with the drug concentration in a range of 0.1-2.5 µg/ml with a detection limit of 0.032 µg/ml. Both approaches were analytically validated based on the guiding rules of the ICH with acceptable results, and were utilized efficiently in the analysis of olanzapine in commercial tablets containing the cited drug. In addition, owing to its high sensitivity and selectivity, the spectrofluorimetric method was applied for drug analysis in spiked human plasma with satisfactory % recoveries. Finally, the greenness of the methods was confirmed using eco-score scale and Analytical Green Evaluation metrics.

Integrated resonance Rayleigh scattering approach utilizing Box-Behnken experimental design for the facile quantification of prucalopride in pharmaceutical tablets and human urine with sustainability assessment.

Prucalopride (PCP) is one of the recent drugs used for the regulation of gastrointestinal tract motility and the treatment of constipation. A new, highly sensitive and fast resonance Rayleigh scattering (RRS) approach was suggested for PCP determination. The approach was based on its reaction of PCP with eosin Y in buffered medium (pH 3.5) to form an ion pair association complex which had a significant enhancement in RRS compared to that of eosin Y or PCP alone. The enhancement of RRS intensity had straight correlation to PCP concentration ranging from 150 to 2000 ng mL-1 with 38 ng mL-1 as LOD and 125 ng mL-1 as LOQ. The measurements were done at a wavelength of 365 nm that provided the maximum sensitivity. All the experimental parameters were studied carefully and optimized via Box-Behnken experimental design. The International Council for Harmonization (ICH) guidelines were employed to validate the suggested method and the obtained results proved the appropriate method performance. The method was efficiently utilized to determine PCP in pure form, pharmaceutical tablets and spiked urine samples with no interferences from the surrounding matrices. Furthermore, the greenness of the suggested procedure was confirmed using different green metric approaches.

A facile on-off fluorescence approach for fluvoxamine determination in pharmaceutical tablets; application to content uniformity testing.

A green-complied spectrofluorimetric approach for quantification of the antidepressant, fluvoxamine, has been established. The method that has been suggested relies on the development of an association complex between fluvoxamine and erythrosine B in an acetate buffer solution. After being excited at 530 nm, the quenching in erythrosine B's native fluorescence caused by complex formation with fluvoxamine was detected at a wavelength of 552 nm. The values of fluorescence quenching at the most optimal reaction conditions were rectilinear at the concentration range of 0.2-2.0 µg mL-1, with a good correlation coefficient (r = 0.9998). The detection limit for the method was 0.03 µg mL-1 while the quantitation limit was 0.09 µg mL-1. The suggested approach has been validated according to the ICH. The established approach was effectively used to determine the drug under study in its dosage form with an average percent recovery of 98.92 ± 0.87 (n = 5), with no effect caused by the existing excipients. The proposed approach was also successfully used for the content uniformity test.

Utility of Cilefa Pink B, a foodstuff dye as a fluoro-substrate in the devising of the first facile green Molecular-mass-Related Fluorescence Sensor for quantifying amlodipine in batched material and dosage forms; content uniformity evaluation.

This study introduces the first and unique Molecular-mass-Related Fluorescence Sensor as the first fluorimetric strategy for determining amlodipine. An environmentally friendly, single-step, and direct spectrofluorimetric approach was utilized to evaluate the analyte. In an acidic setting, combining the amlodipine medication and the fluorescent dye Cilefa Pink B generated an instantaneous ultra-fluorescent product. An increase in dye response after adding amlodipine was proportional to the molecular weight of the generated complex, as measured at 329 nm. was the idea ofthe applied fluorimetric analysis. The complexing process increased the molecular mass from 879.86 to 1288.739 g mol-1. The medication's range of 0.050-1.00 µg mL-1 is directly correlated with this molecular massenlargement. The ideal settings for the changeable parameters of the system were established through an analysis of the response of the amlodipine-Cilefa Pink B system. Furthermore, the developed sensor complied with ICH (International Council for Harmonization) standards. The sensitivity limits were 0.0139 µg mL-1 (for the detection limit, LOD) and 0.042 µg mL-1 (for the quantification limit, LOQ). Additionally, this method effectively recovered the drug in its original and therapeutic dosage forms. Finally, the proposed process's environmental impact was also assessed through different modern greenness evaluation tools.

Integration of a facile sustainable resonance Rayleigh scattering switchable-based system for feasible determination of centrophenoxine, a nootropic and antioxidant agent; application to crude materials and dosage forms.

The proposed research adheres to a certain methodology to ensure that the technique used for analyzing the centrophenoxine drug is sustainable and green. It is important to highlight that several tools that have been recently developed were utilized as potential indicators of environmental sustainability and applicability. The present research presents a novel and entirely innovative method utilizing ultrasensitive spectrofluorimetry for the detection of centrophenoxine (CPX) drug. The employed methodology in this study involved the utilization of one-step, one-pot, and direct spectrofluorimetric technique, which was found to be both efficient and environmentally sustainable in the validation and assessment of the drug. Simply, when CPX and erythrosine B reagent were combined in an acidic environment, the highly resonance Rayleigh scattering product was immediately produced. The sensitivity limits were observed to be within the range of 15-47 ng mL-1, whereas the linearity was assessed to be in the range of 50-2000 ng mL-1. The optimal settings for all modifiable parameters of the system were ascertained through an analysis of centrophenoxine-erythrosine B complexes. Moreover, the system demonstrated compliance with International Council for Harmonization (ICH) specifications without encountering any issues. The suggested process was then rated on different recent environmental safety measuring metrics to see how good it was for the environment. Fortunately, the WAC standards that combine ecological and functional elements utilizing the Green/Red/Blue (RGB 12) design also acclaimed the current analytical technique as a white one. Additionally, a new applicability evaluation tool (BAGI) was employed to estimate the practicability of the planned method in the analytical chemistry field.

The necessity of post-maneuver postural restriction in treating benign paroxysmal positional vertigo: a meta-analytic study.

The objective of this article is to verify the role of postural restrictions after repositioning maneuvers in treating patients with benign paroxysmal positional vertigo (BPPV). The study included published articles yielded by a Pubmed search concerning post-maneuver postural restriction in treating BPPV. The search was limited to articles published in English language in the last three decades. The search was done on 1/11/2011. For the 18 relevant articles, we applied our inclusion and exclusion criteria and only 9 articles were included. The data collected from each article were statistically analyzed utilizing meta-analytic Review Manager (RevMan 5.1) software. (Version: 5.1.0.0). There were no significant differences between patients instructed with postural restriction after undergoing repositioning maneuver and patients left free to move after undergoing repositioning maneuver with regard to the presence or absence of post-maneuver symptoms. In conclusion, post-maneuver restrictions do not add to the success of the treatment of BPPV and there is no reason to submit patients to these impractical instructions.

Utility of Cilefa Pink B, a food dye in a facile decoration of the first green molecular-size-based fluorescence probe (MSBFP) for determining trimebutine; application to bulk, dosage forms, and real plasma.

This research presents the first novel green molecular-size-based fluorescence probe (MSBFP) as a spectroscopic strategy for detecting the Trimebutine drug. The method used a green, one-pot, direct spectrofluorimetric methodology to validate and assess the medication. Trimebutine drug and Cilefa Pink B formed an immediate ultra-fluorescent complex when mixed in an acidic environment. The fluorimetric study relied on Trimebutine's amplification of the dye response, which correlated to the generated complex's molecular size at 361 nm. Upon complexation, the molecular mass has grown from 504.5 to 1384.4 g mol-1. This growth is proportionally coupled to the drug concentration range of 0.035-1.5 µg mL-1. The lower and upper limits of the sensitivity varied from 0.010 and 0.029 µg mL-1, respectively. Trimebutine-Cilefa Pink B complexes were analyzed to determine optimal values for all the tunable system variables. Also, The International Council for Harmonization (ICH) requirements were successfully met by the system. In addition, this method effectively retrieved the drug in the intended pharmaceutical dosages. A significant achievement was using the developed fluorimetric method to monitor the drug of interest in human biofluids. The environmental friendliness of the planned procedure was then evaluated.

The first facile optical density-dependent approach for the analysis of doxorubicin, an oncogenic agent accompanied with the co-prescribed drug; paclitaxel.

Doxorubicin (DRB) is an anthracycline oncogenic drug extracted from cultures of Streptomyces peucetius var. caesius. It is frequently recommended as an anti-neoplastic agent for the treatment of diverse malignancies. It exerts its antineoplastic effect either via inhibiting the enzyme topoisomerase II and/or via intercalation to DNA or reactive oxygen species generation. In the present article, the direct, simple, one-pot, somewhat eco-safe, and non-extractive spectrophotometric system was executed to track doxorubicin, a chemotherapeutic remedy, in the presence of paclitaxel, a naturally occurring Taxan antineoplastic radical, through the greenness rated method. DRB's optical density was studied in various mediums and solvents to develop the current approach. An acidic ethanolic solution was found to increase the optical density of the sample significantly. At 480 nm., the most remarkable optical density was obtained. Various experimental factors, including intrinsic media, solvent, pH, and stability time, were investigated and controlled. The current approach achieved linearity within the 0.6-40.0 µg mL-1 range, accompanied by a limit of both detection and quantification (LOD and LOQ) of 0.18 and 0.55 µg mL-1, correspondingly. The approach was validated under the ICH guidelines (Quality Guidelines). The system's greenness and enhancement degree were estimated.

Facile utility of felumin, a biological dye for the first fluorimetric determination of l-tetramisole drug through an "on-off fluorescence" strategy.

l-Tetramisole is an anti-nematode and immunomodulating agent employed medically to treat diseases caused by worms. It is also used as an immune system-modifying agent in rheumatoid arthritis and as assistant therapy in treating cancers in the colorectal, head, and neck regions. Felumin is a safe food dye used in feed additives, flavors, biostaining, and recently, in analytical tracking. This is the first innovative spectrofluorimetric approach to l-Tetramisole drug analysis. It is both efficient and environmentally benign and was evaluated and validated in this investigation using a green, one-pot, and direct spectrofluorimetric technique. Instant complexes were created by combining l-Tetramisole and Felumin in an acidic solution. The fluorometric investigation was performed based on the off-effect strategy of l-Tetramisole on the emission amplitude of a biological dye (Felumin) at 557.5 nm. The linear range was from 0.1 to 1.7 µg mL-1, with sensitivity limits of 0.020 and 0.061 µg mL-1, respectively. Analytical modulation of l-Tetramisole-Felumin complexes was done for all system parameters. The system was found to meet ICH criteria. Moreover, this technique successfully recovered the substance in the prescribed medicinal dosage forms. The created fluorimetric technique was also successfully employed to track the drug of interest in human biofluids, which was a major accomplishment. The kinetics of the reaction system was also studied further. Finally, the proposed method's environmental friendliness was evaluated on the eco-scale.

A novel and unusual utility of the cardiosintol drug as a fluoro-prober in the amendment of a highly fluorescent module for determining the non-fluorescent N-acetylcysteine drug.

It is common to use reagents to determine the drugs by exploiting the properties of these reagents in the development of fluorescence of the target drug or sometimes increasing its intensity; this is the usual and predominant in the methods used in various techniques. But using a drug as a reagent to analyze another drug is unique, unusual, and uncommon; that's the idea of this paper. This is possible by creating a chemical modulation in the drug's structure using another drug. Targeted analyte molecules (N-acetylcysteine, as an example) that lack fluorogenic or chromophoric moieties cannot be monitored or evaluated without undergoing structural modification. Thus, the chemical mending of the analyte's molecular structure can achieve the transformational process. This protocoled analytical method generates an amended fluorescence sensation that can be chased fluorimetrically at 441 nm (emission) following excitation at 339 nm. When o-dialdehyde, diformylbenzene, a non-fluorescent moiety, is added to a solution of non-fluorescent analyte in the presence of cardiosintol drug, at a specific pH, the target drug-thiol moiety can be amended into a highly fluorescent compound. This study presented a sensitive and feasible fluorometric test for acetylcysteine. The response is linear throughout the range of 0.05-0.80 µg mL-1. Quantum yield and procedure validation were evaluated according to I.C.H. standards. The formed mutated product was successfully applied to the precise assessment of the studied drug in batch powder and dose form(s), with no impact from excipients. Compared to the referenced publication, the outcomes demonstrate remarkable precision and accuracy.

Prevalence, antibiotic resistance patterns, and biofilm formation ability of Enterobacterales recovered from food of animal origin in Egypt.

Background and Aim: The majority of animal-derived food safety studies have focused on foodborne zoonotic agents; however, members of the opportunistic Enterobacteriaceae (Ops) family are increasingly implicated in foodborne and public health crises due to their robust evolution of acquiring antimicrobial resistance and biofilms, consequently require thorough characterization, particularly in the Egyptian food sector. Therefore, this study aimed to determine the distribution and prevalence of Enterobacteriaceae family members in animal-derived foods, as well as their resistance to important antimicrobials and biofilm-forming potential. Materials and Methods: A total of 274 beef, rabbit meat, chicken meat, egg, butter, and milk samples were investigated for the presence of Enterobacteriaceae. All isolated strains were first recognized using traditional microbiological techniques. Following that, matrix-assisted laser desorption ionization-time of flight mass spectrometry was used to validate the Enterobacteriaceae's identity. The isolated enterobacteria strains were tested on disk diffusion and crystal violet quantitative microtiter plates to determine their antibiotic resistance and capacity to form biofilms. Results: There have been thirty isolates of Enterobacteriaceae from seven different species and four genera. Out of the three food types, Pseudomonas aeruginosa had the highest prevalence rate (4.1%). With three species, Enterobacter genera had the second-highest prevalence (3.28%) across five different food categories. In four different food types, the Klebsiella genera had the second-highest distribution and third-highest incidence (2.55%). Almost all isolates, except three Proteus mirabilis, showed prominent levels of resistance, particularly to beta-lactam antibiotics. Except for two Enterobacter cloacae and three P. mirabilis isolates, all isolates were classified as multidrug-resistant (MDR) orextensively multidrug-resistant (XDR). The multiple antibiotic resistance index (MARI) of the majority of isolates dropped between 0.273 and 0.727. The highest MARI was conferred by Klebsiella pneumoniae, at 0.727. Overall, 83.33% of the isolates had strong biofilm capacity, while only 16.67% exhibited moderate capacity. Conclusion: The MDR, XDR, and strong biofilm indicators confirmed in 83.33% of the currently tested Enterobacteriaceae from animal-derived foods suggest that, if not addressed, there may be rising risks to Egypt's economy and public health.

Brief report first report of the in vitro ovicidal activity of camel milk and its fractions on zoonotic-liver fluke (Fasciola gigantica) eggs.

Fasciola gigantica is one of the worldwide parasites that cause livestock and human illnesses. Chemotherapy is now the primary therapeutic option for its treatment. Drug abuse has led to the emergence of drug-resistant strains. As a result, there is an urgent need to discover natural and efficient anthelmintics against Fasciola spp. The study aims to evaluate the ovicidal activities of camel milk and its fractions on F. gigantica eggs. In the in vitro assay of F. gigantica eggs were submitted to different concentrations (0.5% and 1%) of camel milk fractions; Camel Milk Whey (CMW), Camel Milk Casein (CMC), and Skimmed Camel Milk (SCM) as well as a positive control (PC) of Nitroxynil (100 mg/ml) and a negative control (NC) with physiological saline. The Egg Hatching Assay (EHA) results showed that camel milk fractions exhibited ovicidal activity, especially CMW, and CMC, which showed 97.58 ± 0.58 and 96.9 ± 1.99 ovicidal activity, respectively, at a concentration of 1% after 15 days of treatment compared to PC, which exhibited 91.75 ± 4.95 ovicidal activity. The egg hatching ratios were 1.67% and 2.33% for CMW and CMC, respectively, compared to 70.17% for the NC and 6% for the PC. The LC50 values for CMW and CMC on the 15th day of treatment were 0.20 and 9.13, respectively. From the results above, we can infer that camel milk and its fractions are promising as a new alternative for fascioliasis control.

Facile decoration of one-pot fluorescence probe-patterned reaction for sensing and ultrasensitive determination of tradjenta, a new type 2 diabetes oral therapy.

Type 2 diabetes can be cured by using tradjenta (also known as Linagliptin), a new therapeutic drug that is an inhibitor of the dipeptidyl peptidase-4 enzyme. Tradjenta is administered orally alone or in combination with metiguanide or empagliflozin. An easy and specific fluorimetric analysis of Tradjenta was developed and demonstrated in the present investigation. The Hantzsch reaction method, which generates a fluorescent dihydropyridine derivative, is the basis of this assay. In a Toerell-Stenhagen buffered solution, the unsubstituted amine group of Tradjenta interacted with 2,4-Pentadione/Oxomethane. Spectrofluorimetry was utilized for this investigation at an excitation/emission wavelength of 421/480 nm. When comparing the Tradjenta concentration to the tracked fluorimetric signal, the method revealed linearity over the concentration range of 0.05 to 1.2 µg/mL. By strictly altering system parameters and analyzing the validation factors following International Council for Harmonisation (ICH) requirements, the outcomes were achieved. Finally, the proposed approach was successfully applied to assay the drug not only in its raw form and prescribed formulations but also to evaluate the tablet's uniformity of content.

Mathematical processing of absorption as green smart spectrophotometric methods for concurrent assay of hepatitis C antiviral drugs, Sofosbuvir and Simeprevir: application to combined pharmaceutical dosage forms and evaluation of the method greenness.

The present work was developed to create three rapid, simple, eco-friendly, cheap spectrophotometric methods for concurrent assay of Sofosbuvir (SOF) and Simeprevir (SMV) in their pure, laboratory prepared mixture and pharmaceutical dosage form with high degree of accuracy and precision. Three methods were developed including iso-absorptive point, ratio subtraction and dual wavelength. The linear range of the proposed methods was 3.0-50.0 and 2.0-50.0 µg mL-1 for SMV and SOF, respectively. The proposed methods were validated according to ICH guidelines in terms of linearity, accuracy, precision, limit of detection and limit of quantitation. The proposed approach is highly simple and the procedure is environmentally green making it suitable for the drug analysis in routine works.

A green fluorescence turn-off system for meclofenoxate determination by Cilefa Pink B dye.

Because of their high extinction indices, high quantum yields, and propensity to attach to biomolecules, xanthene dyes, and related compounds have attracted more attention for analytical drug labelling and monitoring. The halogen-substituted xanthene dye, Cilefa Pink B, has also been adapted for usage in the food and pharmaceutical industries as well as for diagnostic purposes. Cilefa Pink B dye is a promising reagent for the quantitative analysis of numerous analytes due to its natural fluorescence characters. MFX is a powerful antioxidant serving as a nootropic agent, motivating glucose uptake and oxygen levels and improving metabolic energy in the brain. The first novel fluorimetric method for quantifying the cerebral circulatory enhancer meclofenoxate is presented in this article. This study used a green, single-pot, and direct fluorimetric strategy to quantify and validate meclofenoxate. A rapid association complex was designed using meclofenoxate and the Cilefa Pink B dye in a weakly acidic solution. The fluorometric assay was performed based on the turn-off effect of meclofenoxate on the fluorescence magnitude of the bio pigment (Cilefa Pink B) at 556.5 nm. The linearity is within the range of 0.08-1.9 µg mL-1. Regarding all system parameters, meclofenoxate-Cilefa Pink B coupled complexes were regulated analytically. The system was compliant with ICH guidelines as well. Meclofenoxate in indicated therapy dosage forms was successfully recovered using the designed procedure. The planned fluorescence detection approach has also been effectively utilized to monitor the analyte of interest in its crude and commercial forms. Additionally, the reaction kinetics were studied further, and the product was characterized and confirmed spectroscopically. An eco-scale was applied to rate the environmental friendliness of the designed method.

[Severe tophaceous gouty arthritis can be treated but is still overlooked in healthcare].

This is a case report of a 68-year-old male with severe tophaceous gouty arthritis, diabetes, kidney impairment and ischaemic heart disease. The patient had repeated attacks of acute gout during a 20-year period and excessive tophaceous depositions. Walking was severely hampered by feet deformity and pain. No urate-lowering therapy was initiated despite contacts to several medical specialties. After the diagnosis was established, the patient was finally treated with allopurinol with an obvious beneficial effect on his symptoms and the size of the tophaceous depositions.

A simple single jar "on-off fluorescence" designed system for the determination of mitoxantrone using an eosin Y dye in raw powder, vial, and human biofluids.

In this work, a direct, simple, one-pot, and green spectrofluorimetric approach was applied to measure mitoxantrone, a chemotherapeutic agent, through a green validated method. The suggested approach focused on establishing an easy association complex combining mitoxantrone and the eosin Y reagent in a slightly acidic solution. The fluorometric analysis was dependent on off-mitoxantrone action on the emission intensity of the dye (eosin Y) at 544.5 nm (excitation = 301 nm). The devised system has a linear range of 0.07-2.5 µg mL-1 and a detection limit of 0.016 µg mL-1. All system parameters for the formation of mitoxantrone-eosin Y complexes were modulated analytically. Also, the system was reviewed in agreement with ICH criteria. Furthermore, the proposed model was approached to quantify mitoxantrone in its pharmaceutical vial dosage form with high recoveries. Also, the proposed spectroscopic design was efficiently employed to detect the investigated drug in body fluids (blood and urine). Lastly, the designed method was evaluated from a greenness point of view according to eco-scale.